Antiepileptic drugs and thyroid function

Journal of Pediatric Endocrinology and Metabolism

Volumn 21, Issue 5, 2008, Pages 401-408

  Verrotti, Alberto ^a   Scardapane, Alessandra ^a   Manco, Rossella ^a   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Carbamazepine; Epilepsy; Phenytoin; Thyroid function; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; CYTOCHROME P450; DIAZEPAM; ETIRACETAM; GABAPENTIN; GLUTAMATE RECEPTOR; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; LORAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; THYROID HORMONE RECEPTOR; THYROXINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ANTICONVULSANT ACTIVITY; BIPOLAR DISORDER; CLINICAL TRIAL; DRUG BINDING SITE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; ENZYME INHIBITION; FOCAL EPILEPSY; FREE LIOTHYRONINE INDEX; GRAND MAL SEIZURE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; METABOLIC DISORDER; MONOTHERAPY; MOOD DISORDER; NEUROPATHIC PAIN; NONHUMAN; REVIEW; SIDE EFFECT; SOMNOLENCE; THYROID DISEASE; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL; THYROID HORMONE METABOLISM; THYROIDITIS; THYROTROPIN BLOOD LEVEL; THYROTROPIN RELEASE; THYROXINE BLOOD LEVEL; TONIC CLONIC SEIZURE;

EID: 46049102006     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2008.21.5.401     Document Type: Review

References (82)

1. Oppenheimer JH, Fischer LV, Nielson KM, Jailer JW. Depression of the serum protein-bound iodine level by diphenyly-dantoin. J Clin Endocrinol Metab 1961; 21: 252-262.
2. Hilton EJ, Hosking SL, Betts T. The effect of anti-epileptic drugs on visual performance. Seizure 2004; 13: 113-128.
3. Strolin Benedetti M, Whomsley R, Baltes E, Tonner F. Alteration of thyroid hormone homeostasis by anti-epileptic drugs in humans: involvement of glucuronosyl-transferase induction. Eur J Clin Pharmacol 2005; 61: 863-872.
4. Cavlieri RR, Sung LC, Becker CE. Effects of phenobarbital on thyroxine and triiodothyronine kinetics in Graves' disease. J Clin Endocrinol Metab 1973; 37: 308-316.
5. Curran PG, De Groot LJ. The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. Endocr Rev 1991; 12: 135-150.
6. A-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann Med 1997; 29: 275-282.
7. Constantinou C, Bolaris S, Valcana T, Margarity M. Diazepam affects the nuclear thyroid hormone receptor density and their expression levels in adult rat brain. Neurosci Res 2005; 52: 269-275.
8. Schwarz DJ, Griget G. Phenytoin and carbamazepine: potential- and frequency-dependent block of Na current in mammalian myelinated nerve fibers. Epilepsia, 1989; 30: 286-294.
9. Liewendahl K, Majuri H, Helenius T. Thyroid function tests in patients on long-term treatment with various anticonvulsant drugs. Clin Endocrinol (Oxf) 1978; 8: 185-191.
10. Bentsen KD, Gram L, Veje A. Serum thyroid hormones and blood folic acid during monotherapy with carbamazepine or valproate. A controlled study. Acta Neurol Scand 1983; 67: 23 5-241.
11. Connell JMC, Rapeport WG, Gordon S. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol 2001; 25: 43-46.
12. Vainionpaa LK, Mikkonen K, Rattya J, Knip, M, Pakarinen AJ, Myllyla VV, Isojarvi JIT. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine or valproate monotherapy and after withdrawal of medication. Epilepsia 2004; 45: 197-203.
13. Isojarvi JIT, Pakarinen AJ, Myllyla VV. Thyroid function with antiepileptic drugs. Epilepsia 1992; 33: 142-148.
14. Eiris-Punal J, Del Rio-Garu M, Del Rio-Garma MC, Lojo-Rocamonde S, Novo-Rodrigue I, Castrci-Gago M. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 1999; 40: 1761-1766.
15. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F. Thyroid hormones in epileptic children receiving carbarnazepine and valproic acid. Pediatr Neurol 2001; 25: 43-46.
16. Isojarvi JIT, Pakarinen AJ, Myllyla VV. Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol 1989; 46: 1175-1178.
17. Isojarvi JIT, Airaksienen KEJ, Mustonen JN, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Thyroid and myocardial function after replacement of carbamazepine by oxcarbazepine. Epilepsia 1995; 36: 810-816.
18. Hamed SA, Harried EA, Kandil MR, El-Shereef HK, Abdellah MM, Omar H. Serum thyroid hormone balance and lipid profile in patients with epilepsy. Epilepsy Res 2005; 66: 173-183.
19. Simko J, Horacek J. Carbamazepine and risk of hypothyroidism: a prospective study. Acta Neurol Scand 2007; 116: 317-321.
20. Friis ML, Kristensen O, Boas J. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-227.
21. Wamil AW, Schmutz M, Portet C, Feldmann KF, McLean MJ. Effects of oxcarbazepine and 10-hydroxy-carbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 1994; 271: 301-308.
22. Larkin JG, McKee PJW, Forrest G. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991; 31: 65-71.
23. Isojarvi JIT, Turkka J, Pakarinen AJ, Kotila M, Rattya J, Myllyla VV. Thyroid function in men taking carbamazepine, oxcarbazepine or valproate for epilepsy. Epilepsia 2001; 42: 930-934.
24. Cansu A, Serdaroglu A, Camurdan O, Hirfanoglu T, Bideci A, Gucuyener K. The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia 2006; 47: 1855-1859.
25. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39: 95-99,
26. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick, ed. New Trends in Epilepsy Management: The Role of Gabapentin. Royal Society of Medicine Services International Congress and Symposium Series No. 198. Royal Society of Medicine Services, 1993; 41-46.
27. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-427.
28. Frye MA, Luckenbaugh D, Kimbrell TA, Constantino C, Grothe D, Corà-Locatelli G, Ketter TA. Possible gabapentin- induced thyroiditis [Letter]. J Clin Psychopharmacol 1999; 19: 94-95.
29. Buoni S, Grosso S, Fois A. Lamotrigine in typical absence epilepsy. Brain Dev 1999; 21: 303-306.
30. Matsuo F. Lamotrigine. Epilepsia 1999; 40 (Suppl 5): S30-S36.
31. Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharm 1999; 9 (Suppl 4): S119-S123.
32. Engle PM, Peck AM. Lamotrigine for the treatment of bipolar disorder. Ann Pharmacother 2000; 34: 258-262.
33. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double blind randomized controlled trial. Ann Clin Psychiatry 2000; 12: 5-10.
34. McElroy SL, Keck PE Jr. Pharmacological agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48: 539-557.
35. Devaulder J De Laat M. Lamotrigine in the treatment of chronic refractory neuropathic pain. J Pain Symptom Manage 2000; 19: 398-403.
36. Vadi PP, HAmann W. The use of lamotrigine in neuropathic pain. Anesthesia 1998; 53: 808-809.
37. D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia. 1999; 19: 64-66.
38. Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, Mezei M, Hardy MA, Snow B, Martin W, Hayden MR. Influence of lamotrigine on progression of early Huntington disease: a randomised clinical trial. Neurology 1999; 53: 1000-1011.
39. MacDonald R, Greenfield LJ. Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol 1997; 10: 121-128.
40. Meldrum BS. Update on the mechanisms of action of antiepileptic drugs. Epilepsia 1996; 37 (Suppl 6): S4-S11.
41. Stefani A, Spadoni F, Bernardi G. Voltage gated calcium currents: targets for epileptic drug therapy? Epilepsia 1997; 38: 959-965.
42. 2+ currents in cortical neurons: functional implications. Eur J Pharmacol 1996; 307: 113-116.
43. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999; 40 (Suppl 5): S2-S10.
44. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38: 119-130.
45. Burgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 190; 36: S1-S7.
46. Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, Wargin WA, Lai AA, Hubbell J, Chem WH, Allsup T, Otto V. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991; 10: 191-200.
47. Garnett WR. Lamotrigine pharmacokinetics. J Child Neurol 1997; 12: S10-S15.
48. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32: 554-563.
49. Tanaka E. Clinically significant pharmacokinetics drug interaction between antiepileptic drugs. J Clin Pharm Ther 1999; 24: 87-92.
50. Anderson GD, Gidal BE, Levy RH Yau MK, Wolf KG, Lai AA. Effect of lamotrigine (LTG, Lamictal) on the pharmacokinetics and biotransformation of valproate. Epilepsia 1992; 33: 82.
51. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press, 1990.
52. Cerreghino JJ, Biton V, Abou-Khalil MD. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242.
53. Loscher W, Honack D, Bloms-Funke P. The novel antiepileptic drug levetiracetam (ucb L 059) induces alterations in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res 1996; 735: 208-216.
54. Hans G, Nguyen L, Rocher V. Levetiracetam: no relevant effect on ionotropic excitatory glutamate receptors. Epilepsia 2000; 41: 37.
55. Merritt HH, Putnam TJ. A new series of anticonvulsant drugs tested by experiments on animals. Arch Neurol Psychiatry 1938; 39: 1003-1015.
56. De Lorenzo RJ. The epilepsies. In: Bradley WG, Daroff RB, Fenichel GM, et al., eds. Is Neurology in Clinical Practice. Stoneham, MA: Butterworth Publishers, 1989; 1443-1478.
57. De Lorenzo RJ, Dashefsky L. Anticonvulsants. Hand Neurochem 1985; 9: 363-403.
58. De Lorenzo RJ. Status epilepticus. Curr Ther Neurol Dis 1990; 3: 47-53.
59. De Lorenzo RJ. Management of status epilepticus. Virginia Med Q 1996; 123: 103-111.
60. Rootwelt K, Ganes T, Johannessen SI. Effects of carbarnazepine, phenytoin and phenobarbitone on serum levels of thyroid hormones and thyrotropin in humans. Scand J Clin Lab Invest 1978; 38: 731-736.
61. Yeo PPB, Bates D, Howe JG, Ratcliffe WA, Schardt CW, Heath A, Evered DC. Anticonvulsants and thyroid function. Br Med J 1989; 1: 1581- 583.
62. Fichsel H, Knöpfle G. Effects of anticonvulsant drugs on thyroid hormones in epileptic children. Epilepsia 1978; 19: 323-336.
63. Chin W, Schussler GC. Decreased serum free thyroxine concentration in patients treated with diphenylhydantoin. J Clin Endocrinol Metab 1968; 28: 181-186.
64. Larsen PR, Atkinson AJ Jr, Wellman HN, Goldsmith RE. The effect of diphenylhydantoin on thyroxine metabolism in man. J Clin Invest 1970; 49: 1266-1279.
65. Hanson JM, Skovsted L, Lauridsen UB, Kirkegaard C, Slersbaek-Nielsen K. The effect of diphenylhydantoin on thyroid function. J Clin Endocrinol Metab 1974; 39: 785-789.
66. Stjernholm MR, Alsever RN, Roolph MC. Thyroid function tests in diphenylhydantoin-treated patients. Clin Chem 1975; 21: 1388-1392.
67. Liewendahl K, Majuri H. Thyroxine, triiodothyronine, and thyrotropin in serum during long-term diphenyl-hydantoin therapy. Scand J Clin Lab Invest 1976; 36: 141-144.
68. Heyma P, Larkins RG, Perry-Keene D, Peter CT, Ross D, Sloman JG. Thyroid hormone levels and protein binding in patients on long-term diphenyhydantoin treatment. Clin Endocrinol (Oxf) 1977; 6: 369-376.
69. Cavalieri RR, Gavin LA, Wallace A, Hammond ME, Cruse K. Serum thyroxine, free T4, triiodothyronine, and reverse-T3 in diphenylhydantoin-treated patients. Metabolism 1979; 28: 1161-1165.
70. Liewendahl K, Helenius T, Majuri H, Ebeling P, Ahlfors UG. Effects of anticonvulsivant and antidepressant drugs on iodothyroxines in serum. Scand J Clin Lab Invest 1980: 40: 767-774.
71. Surks MI, Ordene KW, Mann DN, Kumara-Siri MH. Diphenylhydantoin inhibits the thyrotropin response to thyrotropin-releasing hormone in man and rat. J Clin Endocrinol Metab 1983: 56: 940-945
72. Zhu SQ, Liu XM, Ruan XZ, Cai Z. Changes of thyroid hormone levels in epileptic patients. J Tonji Med Univ 1994; 14: 119-123.
73. Curran PG, DeGroot LJ. The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. Endocr Rev 1991; 12: 135-150.
74. Blackshear JL, Schultz AL, Napier JS, Stuart DD. Thyroxine replacement in hypothyroid patients receiving phenytoin. Ann Intern Med 1983; 99: 341-342.
75. Franklyn JA, Sheppard MC, Ramsden DB. Measurement of free thyroid hormones in patients on long-term phenytoin therapy. Eur J Clin Pharmacol 1984; 26: 633-634.
76. Man B, Brodie MJ, Kalviainen R, Beran R, Berkovic S, Kruse T, Lyby K. Laboratory variables in a comparative monotherapy drug trial with tiagabine (gabitril). Epilepsia 1998; 39: 65.
77. Schechtet PJ. Vigabatrin. In: Meldrum B, Porter RJ, eds. New Anticonvulsivant Drugs. London: John Libbey, 1986; 265-275.
78. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003; 11: 556-562.
79. Ericsson UB, Bjerre I, Forsgren M, Ivarsson SA. Thyroglobulin and thyroid hormones in patients on long-term treatment with phenytoin, carbarnazepine and valproic acid. Epilepsia 1985; 26: 594-596.
80. Bentsen KD, Gram L, Veje A. Serum thyroid hormones and blood folic acid during monotherapy with carbamazepine or valproate. Acta Neurol Scand 1983; 67: 235-241.
81. Yuksel A, Kartal A, Cenani A, Yalgin E. Serum thyroid hormones and pituitary response to thyrotropin-releasing hormone in epileptic children receiving anti-epileptic medication. Acta Paediatr Jpn 1993; 35: 108-112.
82. Bianco E, Rodriguez-Mendizabal M, Gonzalez-Correa JA, Merida F, Lucena MI, Pavia J, Sanchez de la Cuesta, F. Effects of vigabatrin on the thyroid. Eur J Clin Pharmacol 1997; 52: 129.